Home › Research › Risk genes beyond APOE
15 years of longitudinal genetic, clinical, cognitive, imaging, and biochemical measures in DIAN
Alisha J. Daniels, Eric McDade, Jorge J. Llibre‐Guerra, Chengjie Xiong, Richard J. Perrin, Laura Ibáñez, Charlene Supnet‐Bell, Carlos C Cruchaga et al.. npj Dementia, 2026-02-16
Topic: Risk, prevention and care in population studies
Plain-language summary
Abstract The Dominantly Inherited Alzheimer Network Observational Study (DIAN Obs) is a longitudinal, global cohort study investigating brain aging and autosomal dominant Alzheimer’s disease (ADAD), a rare monogenic form of Alzheimer’s disease (AD). Established in 2008 with support from the National Institute on Aging (NIA), DIAN Obs is designed to collect comprehensive and uniform data with the aim to characterize brain biology and clinical trajectory of individuals at risk for ADAD. Mutations in the amyloid protein precursor ( APP ), presenilin 1 ( PSEN1 ), or presenilin 2 ( PSEN2 ) genes cause ADAD with virtually full penetrance and a predictable age at symptomatic onset. Participants, both mutation carriers and non-carriers from affected families, undergo longitudinal clinical and cognitive assessments, neurologic and physical examinations, structural and functional neuro-imaging, and amyloid and tau positron emission tomography (PET). Biospecimens include cerebrospinal fluid, plasma, serum, and whole blood for biochemical, genetic and multi-omic analyses, with brain donation upon death. This dataset enables one of the most detailed longitudinal examinations of the human brain across the continuum from presymptomatic to symptomatic AD. The extensive DIAN Obs data and biospecimen repository provides a globally accessible resource to advance understanding of AD pathophysiology, aging, and the development of preventive and therapeutic interventions.
What this study adds
Evidence grade: Moderate
This is a follow-up (cohort) study. This describes 15 years of the DIAN Observational Study, a global longitudinal cohort collecting genetic, clinical, cognitive, imaging and biochemical data from people at risk for autosomal dominant Alzheimer's disease. It provides a resource to study disease trajectory from presymptomatic to symptomatic stages, but it is not a treatment or prevention trial.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Daniels, A. J., McDade, E., Llibre‐Guerra, J. J., Xiong, C., Perrin, R. J., Ibáñez, L., et al. (2026). 15 years of longitudinal genetic, clinical, cognitive, imaging, and biochemical measures in DIAN. npj Dementia. https://doi.org/10.1038/s44400-025-00047-7
Vancouver
Daniels AJ, McDade E, Llibre‐Guerra JJ, Xiong C, Perrin RJ, Ibáñez L, et al. 15 years of longitudinal genetic, clinical, cognitive, imaging, and biochemical measures in DIAN. npj Dementia. 2026. doi:10.1038/s44400-025-00047-7. PMID: 41709913.
BibTeX
@article{daniels2026-41709913,
author = {Daniels, Alisha J. and McDade, Eric and Llibre‐Guerra, Jorge J. and Xiong, Chengjie and Perrin, Richard J. and Ibáñez, Laura and Supnet‐Bell, Charlene and Cruchaga, Carlos C and others},
title = {{15 years of longitudinal genetic, clinical, cognitive, imaging, and biochemical measures in DIAN}},
journal = {npj Dementia},
year = {2026},
doi = {10.1038/s44400-025-00047-7},
pmid = {41709913},
url = {https://doi.org/10.1038/s44400-025-00047-7}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- Mutations in the amyloid protein precursor ( APP ), presenilin 1 ( PSEN1 ), or presenilin 2 ( PSEN2 ) genes cause ADAD with virtually full penetrance and a predictable age at symptomatic onset.
- Participants, both mutation carriers and non-carriers from affected families, undergo longitudinal clinical and cognitive assessments, neurologic and physical examinations, structural and functional neuro-imaging, and amyloid and tau positron emission tomography (PET).
- Biospecimens include cerebrospinal fluid, plasma, serum, and whole blood for biochemical, genetic and multi-omic analyses, with brain donation upon death.
- This dataset enables one of the most detailed longitudinal examinations of the human brain across the continuum from presymptomatic to symptomatic AD.
- The extensive DIAN Obs data and biospecimen repository provides a globally accessible resource to advance understanding of AD pathophysiology, aging, and the development of preventive and therapeutic interventions.
Why it matters
This describes 15 years of the DIAN Observational Study, a global longitudinal cohort collecting genetic, clinical, cognitive, imaging and biochemical data from people at risk for autosomal dominant Alzheimer's disease. It provides a resource to study disease trajectory from presymptomatic to symptomatic stages, but it is not a treatment or prevention trial.
New to this subject? Start with our plain-English guide: Genetics →
Study details
- Study designcohort study
- Evidence strengthModerate
How this study scored 50/100
Published in a peer-reviewed journal, and it is a cohort study following people over time. Scored zero for sample size, effect reported, studied in people and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (npj Dementia) |
| Journal's citation record | 0 / 4 | Npj Dementia: journal h-index 10 (OpenAlex, 2026-10-29) |
| Study design | 7 / 12 | A cohort study following people over time |
| Strength of evidence | 3 / 5 | Rated “moderate” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 5 / 5 | 2026 — within 1 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 1 / 7 | Cited 2 times (OpenAlex, 2026-10-10) |
| Citations per year | 1 / 5 | 1.0 citations a year over 2 year(s) since 2026 |
| Impact for its field and year | 4 / 6 | Cited 8.3× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 0 / 4 | Cited 2 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 2 / 4 | Last-listed author Jonathan Vöglein: h-index 28 (OpenAlex, whole career) |
| Institution's track record | 3 / 3 | Harvard University: institution h-index 3,235 (OpenAlex) |
| Multicenter collaboration | 3 / 3 | OpenAlex lists 30 institution(s) in 11 countries |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 41709913) |
| Free to read | 2 / 2 | Free to read |
| Total | 50 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 22.
Related studies in Risk genes beyond APOE from nearby years
Also in Risk genes beyond APOE
103 studies in the library are filed under Risk genes beyond APOE with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Risk genes beyond APOE hub.